Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye

摘要

Topical application of soluble tumor necrosis factor receptor antagonist (sTNFRI) is shown to promote corneal transplant survival in a murine model of orthotopic allotransplantation, having a significant effect in prolonging graft survival. Furthermore, the promotion of graft survival is associated with a significant decrease in corneal inflammation. Therefore, sTNFRI and related antagonists to tumor necrosis factor- alpha activity can be used in a therapeutic composition for local prophylaxis and treatment of allograft rejection and a wide array of immunogenic inflammatory diseases of the eye. The composition comprises a therapeutically effective amount of a tumor necrosis factor- alpha antagonist in association with a pharmaceutically acceptable carrier vehicle for local application.